Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular Inc. reported a significant increase in operating income, which rose 47% year-over-year to $18.8 million, alongside a 14% organic revenue growth driven by both price and volume factors. The company achieved an adjusted gross margin of 70.4% and an adjusted operating margin of 26%, coupled with a 23% increase in adjusted EPS, reflecting strong operational efficiency and profitability. Additionally, robust regional growth, particularly in the EMEA and APAC markets, underpins a positive outlook for the company, signaling strong demand for its vascular devices and services.

Bears say

LeMaitre Vascular faces a negative outlook due to several underlying financial risks, including potential technical problems with its key mRidium pump, unexpected competition, and possible regulatory issues with the FDA, which could negatively affect its financial performance. Additionally, the company may encounter challenges related to lower price increases, competitive pressures, slower international market adoption, and reimbursement rate reductions for medical procedures, further threatening profitability. Despite international revenues exceeding expectations at $24.3 million, the risk factors combined with a reliance on revenue growth assumptions indicate a precarious financial position moving forward.

LeMaitre Vascular (LMAT) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 5 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.